Similar to obesity, metabolic pathways involving CerS6 are dysregulated and CerS6-derived C16:0-ceramides are elevated in NAFLD patients and mice [23,29,42]. The gene discussed is CERS6; the disease is metabolic dysfunction-associated steatotic liver disease.